Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 54

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 54
---
Settlement of pre-existing receivable1,055 Purchase price consideration of 81% of GQ Bio30,576 Prior 19% equity investment ownership of GQ Bio realized upon business combination8,315 Total fair value of the GQ Bio Acquisition$38,891 The Company has accounted for the GQ Bio Acquisition using the acquisition method of accounting and, accordingly, has included the assets acquired, liabilities assumed and results of operations in its condensed consolidated financial statements from the acquisition date of February 27, 2025. A $5.7 million indemnification holdback established for potential unidentified liabilities will be settled within 18 months from the acquisition date. In conjunction with the GQ Bio Acquisition, the settlement of the Company’s prior equity investment and notes receivable in GQ Bio were part of the fair value of consideration exchanged. See Note 10, Financial Instruments, for additional information.The preliminary purchase price allocation is based on estimates, assumptions, valuations and other studies which have not yet been finalized. Prior to the finalization of the purchase price allocation, if information becomes available that would indicate it is probable that unknown events had occurred and the amounts can be reasonably estimated, such items will be included in the final purchase price allocation and may change the carrying value of goodwill. The Company is finalizing its valuation of liabilities and tax analyses, and anticipates finalizing the purchase price allocation as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. 

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  11

The following tables set forth the preliminary allocation of the GQ Bio Acquisition purchase price to the estimated fair value of the net assets acquired at the acquisition date (in thousands):Amounts Recognized at the Acquisition Date (as Previously Reported) (a)Measurement Period Adjustments (b)Amounts Recognized at the Acquisition Date (as Adjusted)ASSETS ACQUIREDCash and cash equivalents$1,884 $— $1,884 Accounts receivable900 — 900 Prepaid expenses and other assets120 383 503 Fixed assets 364 — 364 Right-of-use assets1,374 — 1,374 In-process research and development (IPR&D) 22,500 — 22,500 Other noncurrent assets56 — 56 Total assets$27,198 $383